PULMATRIX, INC. Gain (Loss) on Extinguishment of Debt
PULMATRIX, INC. (PULM) reported Gain (Loss) on Extinguishment of Debt of $1.16 million for the 9-month period ending 2015-09-30, per its 10-Q filed 2015-11-12.
Discontinued › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2015-11-12
- PULMATRIX, INC. gain (loss) on extinguishment of debt for the quarter ending 2015-09-30 was $0.00.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month |
|---|---|---|---|
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $1.16M 10-Q · filed 2015-11-12 | |
| 2015-06-30 | $1.16M 10-Q · filed 2015-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |